PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

required to respond	to a collection of information unles	<u>is it displays a valid OMB control</u> number.
	Application Number	09/646,807
-	Filing Date	December 5, 2000
	First Named Inventor	Michael W. GRAHAM
filing)	Art Unit	1636
	Examiner Name	D. Sullivan
7 + 2 Refs + Exhibits A & B	Attorney Docket Number	546322000321

ENCLOSURES (Check all that apply)					
Fee Transmit	1	Drawing(s)	After Allowance Communication to Group		
Fee Atta	ached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment/R	Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Repty Brief)		
After Fin	nal	Petition to Convert to a Provisional Application	Proprietary Information		
Affidavit	ts/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter		
Extension of T	Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):		
Express Abandonment Request X Information Disclosure Statement w/ Form PTO/SB/08a/b (6 pages) Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Request for Refund CD, Number of CD(s) Remarks	Copy of 2 Cited References Exhibit A (379 pages) Exhibit B (20 pages) Return Receipt Postcard		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
	MORRISON & FOERSTER LLP (Customer No. 20872) Michael R. Ward - Reg. No. 38,651				
Signature	Michael RWard				
Date F	February 11, 2005				

I hereby certify that this paper or fee is being deposited with the United States Postal Service under 37 C.F.R. § 1.10 via Express Mail Label No. EL 968416933 US and is addressed to: MAIL STOP: AMENDMENT, Commissioner for Patents, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below:

Dated: February 11, 2005

FEB 11 2005

2-14-05

JU1636

PATENT Docket No. 546322000321

CERTIFICATE OF MAILING

Date of Deposit: February 11, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service under 37 C.F.R. § 1.10 via Express Mail Label No. EL 968416933 US on the date indicated above and is addressed to: MAIL STOP: AMENDMENT, Commissioner for Patents, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Leah Kjellen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Michael W. GRAHAM et al.

Serial No.:

09/646,807

Filing Date:

December 5, 2000

For:

CONTROL OF GENE EXPRESSION

Examiner: D. Sullivan
Group Art Unit: 1636

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted, except for US 2003/0056235 A1. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This application includes in its chain of priority U.S. application 09/100,812, now issued U.S. Patent 6,573,099. The Examiner's attention is directed to the preliminary amendment filed in US 2003/0056235 A1 (copy attached to the enclosed copy of the application as published) which relates to U.S. Patent 6,573,099. U.S. Patent 6,573,099 is the subject of ongoing patent litigation: Benitec Australia Ltd. v. Nucleonics, Inc., Ambion, Inc., and GenScript, Inc., Civil Action No. 04-174 (JFF), U.S. District Court for the District of Delaware. As of February 2004, the litigation has been dismissed with respect to defendants Ambion, Inc. and GenScript, Inc. The litigation is ongoing with respect to Benitec Australia Ltd. and Nucleonics, Inc. The Judge in the ongoing litigation recently denied Nucleonics Inc.'s Motion to Dismiss under 271(e).

Applicants respectfully direct the attention of the Examiner to the titles of the 4548 references (without full copies of the references) attached to this Information Disclosure Statement as Exhibit A. This list was provided to the Applicants by defendant Genscript, Inc. prior to Genscript's dismissal from the ongoing patent litigation suit. Applicants have not separately obtained or reviewed any of the 4548 references (even to confirm that the list actually sets out 4548 references), nor have they examined all of the titles, except to the extent that any of the references have already been in the possession of the Applicants (in which case such reference(s) would have been provided to the Examiner if material and not cumulative with references already provided). Applicants have no reason to believe that the references in the list are material to the claimed invention and have no reason to believe that, even if material, any of the references would not be cumulative in light of the over 270 references already submitted during the prosecution of this patent application, other than the submission by the defendant. The Examiner is requested to review the enclosed list of references.

Applicants further direct the attention of the Examiner to the titles of the additional references (without full copies of the references) attached to this Information Disclosure Statement as Exhibit B. This list was provided to the Applicants by defendant Nucleonics, Inc.

sf-1870913 2

in the litigation as art that Nucleonics, Inc. may rely on in the ongoing litigation. Applicants have not separately obtained or reviewed any of the references listed on Exhibit B, nor have they examined all of the titles, except to the extent that any of the references have already been in the possession of the Applicants (in which case such reference(s) would have been provided to the Examiner if material and not cumulative with references already provided). Applicants have no reason to believe that the references in the list are material to the claimed invention and have no reason to believe that, even if material, any of the references would not be cumulative in light of the over 270 references already submitted during the prosecution of this patent application, other than the submission by the defendant. The Examiner is requested to review the enclosed list of references.

sf-1870913 3

	This In	formation Disclosure Statement is submitted:			
	With the application; accordingly, no fee or separate requirements are required.				
\boxtimes	Before	the mailing of a first Office Action after the filing of a Request for Continued			
	Exami	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R.			
	§ 1.97	(e)(1) has been provided.			
	Within	three months of the application filing date or before mailing of a first Office			
	Action on the merits; accordingly, no fee or separate requirements are required.				
	Howev	ver, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.			
	After receipt of a first Office Action on the merits but before mailing of a final Office				
	Action or Notice of Allowance.				
		A fee is required. A check in the amount of is enclosed.			
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached			
		to this submission in duplicate.			
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee			
		is believed to be due.			
	After mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue fee.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the			
		amount of is enclosed.			
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal			
		form (PTO/SB/17 is attached to this submission in duplicate.)			

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search

sf-1870913 4

Application Serial No. 09/646,807

Docket No. 546322000321

has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **546322000321**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 11, 2005

Respectfully submitted,

Ву:

Michael R. Ward

Registration No. 38,651

Morrison & Foerster LLP 425 Market Street

San Francisco, California 94105-2482

Telephone: (415) 268-6237 Facsimile: (415) 268-7522

Complete if Known Substitute for form 1449/PTO 09/646,807 Application Number INFORMATION DISCLOSURE Filing Date December 5, 2000 STATEMENT BY APPLICANT First Named Inventor Michael W. GRAHAM 1636 Art Unit (Use as many sheets as necessary) D. Sullivan Examiner Name 546322000321 Sheet of 1 Attorney Docket Number

	U.S. PATENT DOCUMENTS				
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where
Initials*	Cite No. ¹	Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear
	AA	US 4,766,072	08-23-1988	Jendrisak et al.	
	AB	US 2003/0056235 A1	03-20-2003	Fire et al.	
		with amendments			
	AC	US 2004/0064842 A1	04-01-2004	Graham et al.	
	AD	US 2004/0237145 A1	11-25-2004	Graham et al.	
	AE	US 2003/0159161 A1	08-21-2003	Graham et al.	
	AF	US 2004/0180439 A1	09-16-2004	Graham et al.	
	AG	US 2004/0266005 A1	12-30-2004	Graham et al.	

FOREIGN PATENT DOCUMENTS						
Evaminar	Cito	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Examiner Cite Initials* No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		
	ВА	WO 97/44450	11-27-1997			

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	•		

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	
1 10 10 0 70		_

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.